These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 39183094)

  • 1. Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis.
    Soto-Lanza F; Glick L; Chan C; Zhong L; Wilson N; Faiz S; Gandhi S; Naing A; Heymach JV; Shannon VR; Franco-Vega M; Liao Z; Lin SH; Palaskas NL; Wu J; Shroff GS; Altan M; Sheshadri A
    Clin Lung Cancer; 2024 Nov; 25(7):624-633.e2. PubMed ID: 39183094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of immune checkpoint inhibitor treatment in non-small cell lung cancer patients with interstitial lung abnormalities: clinical utility of subcategorizing interstitial lung abnormalities.
    Kikuchi R; Watanabe Y; Okuma T; Nakamura H; Abe S
    Cancer Immunol Immunother; 2024 Sep; 73(11):211. PubMed ID: 39235641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study.
    Fujimoto D; Miura S; Yoshimura K; Wakuda K; Oya Y; Yokoyama T; Yokoi T; Asao T; Tamiya M; Nakamura A; Yoshioka H; Haratani K; Teraoka S; Tokito T; Murakami S; Tamiya A; Itoh S; Yokouchi H; Watanabe S; Yamaguchi O; Tomii K; Yamamoto N
    Eur J Cancer; 2021 Jun; 150():63-72. PubMed ID: 33892408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials.
    Kong Y; Hong L; Xu XC; Chen YF; Xu J
    PLoS One; 2024; 19(4):e0301931. PubMed ID: 38683829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.
    Ono K; Ono H; Toi Y; Sugisaka J; Aso M; Saito R; Kawana S; Aiba T; Odaka T; Matsuda S; Saito S; Narumi A; Ogasawara T; Shimizu H; Domeki Y; Terayama K; Kawashima Y; Nakamura A; Yamanda S; Kimura Y; Honda Y; Sugawara S
    Cancer Med; 2021 Jul; 10(14):4796-4804. PubMed ID: 34121358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer.
    Wong A; Riley M; Zhao S; Zimmer J; Viveiros M; Wang JG; Esguerra V; Li M; Lopez G; Kendra K; Carbone DP; He K; Alahmadi A; Kaufman J; Memmott RM; Shields PG; Brownstein J; Haglund K; Welliver M; Otterson GA; Presley CJ; Wei L; Owen DH; Ho K
    J Natl Compr Canc Netw; 2023 Nov; 21(11):1164-1171.e5. PubMed ID: 37935100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
    Moda M; Saito H; Kato T; Usui R; Kondo T; Nakahara Y; Murakami S; Yamamoto K; Yamada K
    Thorac Cancer; 2020 Dec; 11(12):3576-3584. PubMed ID: 33078531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer.
    Petranovic M; McDermott S; Mercaldo S; Little BP; Graur A; Huang K; Fintelmann FJ; Digumarthy SR; Gainor JF
    Clin Lung Cancer; 2023 Dec; 24(8):682-688.e5. PubMed ID: 37758549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer.
    Altan M; Soto F; Xu T; Wilson N; Franco-Vega MC; Simbaqueba Clavijo CA; Shannon VR; Faiz SA; Gandhi S; Lin SH; Lopez P; Zhong L; Akhmedzhanov F; Godoy MCB; Shroff GS; Wu J; Khawaja F; Kim ST; Naing A; Heymach JV; Daniel-Macdougall C; Liao Z; Sheshadri A
    Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):630-639. PubMed ID: 37507279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.
    Balaji A; Hsu M; Lin CT; Feliciano J; Marrone K; Brahmer JR; Forde PM; Hann C; Zheng L; Lee V; Illei PB; Danoff SK; Suresh K; Naidoo J
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
    Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
    Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical course and prognosis of patients with lung cancer who develop anticancer therapy-related pneumonitis.
    Matsubara T; Yamaguchi M; Jinnouchi M; Takamori S; Fujishita T; Toyozawa R; Ito K; Shimokawa M; Seto T; Okamoto T
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1857-1864. PubMed ID: 33387034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
    Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
    Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Nishiyama O; Shimizu S; Haratani K; Isomoto K; Tanizaki J; Hayashi H; Yamazaki R; Oomori T; Nishikawa Y; Sano A; Nakagawa K; Tohda Y
    BMC Pulm Med; 2021 May; 21(1):155. PubMed ID: 33964920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review.
    Zhang T; Xu K; Bi N; Zhang L; Jiang W; Liang J; Deng L; Wang X; Wang J; Wang J; Wang L
    Thorac Cancer; 2020 Oct; 11(10):2916-2923. PubMed ID: 32833338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study.
    Sawa K; Sato I; Takeuchi M; Kawakami K
    Cancer Immunol Immunother; 2023 Mar; 72(3):591-598. PubMed ID: 35994088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.